New Models Could Improve Prostate Cancer Screening
New diagnostic tools may help men with mid-range PSA levels avoid unnecessary biopsies.
Updated on Oct. 27, 2026 in Men’s Health
Live Poll
Would you trust a machine-learning model to decide if you need a biopsy for prostate cancer?
Researchers have developed new machine-learning models using routine blood test data to improve prostate cancer screening. These tools could help men with mid-range PSA levels avoid unnecessary biopsies.
Why it matters
Prostate-specific antigen (PSA) levels between 4 and 10 ng/mL often yield inconclusive results, leading to many biopsies that find no cancer. These new models aim to improve accuracy and reduce the frequency of invasive follow-up procedures for men in this range.
A study of 1,758 men for development and 9,524 for external validation evaluated machine-learning models using routine blood tests for those with PSA levels of 4-10 ng/mL. The model achieved an internal AUC of 0.825 and significantly reduced unnecessary biopsies compared to total PSA alone.
The players
ESMO Annual Congress
A major international oncology forum where researchers share advancements in cancer diagnosis and treatment.
The details
The models integrate routine hematologic and biochemical blood markers with standard PSA measurements to generate a more nuanced risk score. By analyzing patterns in electronic medical records alongside these blood tests, the machine-learning algorithm identifies men who are more likely to harbor clinically significant cancer. This approach shifts the focus from a single PSA threshold to a multidimensional profile, allowing for a more personalized assessment of the need for a biopsy.
Timeline
2020-2024: Data collection for development and validation cohorts.
October 23-27, 2026: Presentation of results at the ESMO Annual Congress.
Health Landscape
This development addresses the persistent challenge of PSA screening sensitivity, which remains a cornerstone of early prostate cancer detection. It reflects a broader trend of integrating multi-variable machine learning into established diagnostic pathways to improve clinical decision-making.
If you have PSA levels in the 4-10 ng/mL range, discuss with your doctor whether additional blood markers could help refine your cancer risk. Understanding the limitations of current tests is an important step before deciding on invasive procedures like biopsies.
The takeaway
These models suggest that adding routine blood markers to PSA screening may soon offer a more precise way to manage prostate cancer risk. If you are tracking your PSA levels, ask your physician about the clinical markers that might improve the accuracy of your individual screening results.
Further reading
For more on evolving screening guidelines, visit our section on Men’s Health.
Source note: This article includes information reported by Urotoday.
Live Poll
Would you trust a machine-learning model to decide if you need a biopsy for prostate cancer?
